Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)

European Radiology

Volumn 23, Issue 5, 2013, Pages 1250-1259

  Deray, Gilbert ^a   Rouviere, Olivier ^b,c   Bacigalupo, Lorenzo ^c,d   Maes, Bart ^e   Hannedouche, Thierry ^f   Vrtovsnik, François ^g   Rigothier, Claire ^h   Billiouw, Jean Marie ⁱ   Campioni, Paolo ^j   Ferreiros, Joaquin ^k   Devos, Daniel ^l   Alison, Daniel ^m   Glowacki, François ⁿ   Boffa, Jean Jacques ^o   Marti Bonmati, Luis ^p  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d GALLIERA HOSPITAL   (Italy)

^e Heilig Hartziekenhuis Roeselare ^*  (Belgium)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g BICHAT HOSPITAL   (France)

^h HÔPITAL PELLEGRIN   (France)

ⁱ OLV HOSPITAL   (Belgium)

^j UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l GHENT UNIVERSITY HOSPITAL   (Belgium)

^m SERVICE DE DERMATOLOGIE   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o HÔPITAL TENON   (France)

^p UNIVERSITY OF VALENCIA   (Spain)

more..

Author keywords

Gadolinium based contrast agent induced nephropathy; Gd DOTA; Meglumine gadoterate; MRI; Nephrogenic systemic fibrosis

Indexed keywords

GADOTERATE MEGLUMINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTRAST ENHANCEMENT; CONTROL GROUP; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMATOMA; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SCREENING; SIDE EFFECT; TOOTH PAIN;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; DRUG TOXICITY; EUROPE; FEMALE; HETEROCYCLIC COMPOUNDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877151894     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-012-2705-x     Document Type: Article

References (25)

1. Stacul F, van der Molen AJ, Reimer P, et al. (2011) on behalf of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527-2541
2. Rao QA, Newhouse JH (2006) Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 239:392-397
3. Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654-668
4. Perazella MA (2008) Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 3:67-75
5. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G (2009) Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250:618-628
6. Bellin MF, Deray G, Assogba U, et al. (1992) Gd-DOTA: evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10:115-118
7. Ishiguchi T, Takahashi S (2010) Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging. Results of a post-marketing surveillance study in Japan. Drugs RD 10:133-145
8. Maurer M, Heine O, Wolf M, Durmus T, Wagner M, Hamm B (2012) Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: Results in more than 84,000 patients. Eur J Radiol 81:885-890
9. Ergün I, Keven K, Uruç I, et al. (2006) The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21:697-700
10. Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354:2473-2483
11. Zou Z, Ma L (2011) Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol 56:65-73
12. Marckmann P, Skov L, Rossen K, et al. (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
13. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 188:586-92
14. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 42:139-145
15. Townsend RR, Cohen DL, Katholi R, et al. (2000) Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis 36:1207-1212
16. Newhouse JH, Kho D, Rao QA, Starren J (2008) Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. Am J Roentgenol 191:376-382
17. Erley CM, Bader BD, Berger ED, et al. (2004) Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. Nephrol Dial Transplant 19:2526-2531
18. Briguori C, Colombo A, Airoldi F, et al. (2006) Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67:175-180
19. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS (2003) Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38:313-318
20. Chien CC, Wang HY, Wang JJ, et al. (2011) Risk of acute kidney injury after exposure to gadolinium-based contrast in patients with renal impairment. Ren Fail 33:758-764
21. Hoffmann U, Fischereder M, Reil A, Fischer M, Link J, Krämer BK (2005) Renal effects of gadopentetate dimeglumine in patients with normal and impaired renal function. Eur J Med Res 10:149-154
22. Thomsen HS (2004) Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 14:1654-1656
23. Agkun H, Gonlusen G, Cartwright J Jr, Suki WN, Truong LD (2006) Are gadolinium-based contrast media nephrotoxic? A renal biopsy study. Arch Pathol Lab Med 130:1354-1357
24. Natalin RA, Prince MR, Grossman ME, Silvers D, Landman J (2010) Contemporary applications and limitations of magnetic resonance imaging contrast materials. J Urol 183:27-33
25. European Medicines Agency document (Gadolinium-containing contrast agent and nephrogenic systemic fibrosis: long-term consequences of retention in human skin and bone) (2010) EMA/425304/2010 Rev. 1 Website http://www.ema.europa.eu/ docs/en-GB/document-library/Other/2010/07/WC500094268.pdf